UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2134-2139

2012

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

Annals of hematology, 2014-05, Vol.93 (5), p.723-733

2014

Link zum Volltext

Verfügbarkeit prüfen

Macrocytosis Case (Out of Print)

MedEdPORTAL, 2007-01, Vol.3

Besa, Emmanuel

2007

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Low Dose 13 Cis-Retinoic Acid and Alpha Tocopherol Improves Survival Compared to High Dose Therapy for 6 Months In LOW and INT-1/2 Stage MDS: Role for Prevention Trial

Blood, 2011-11, Vol.118 (21), p.5053-5053

2011

Link zum Volltext

Verfügbarkeit prüfen

The Use of Infliximab to Control Recurrent Cytokine Storms in EBV-Associated Angioimmunoblastic Lymphoma and Hemophagocytic Syndrome

Blood, 2012-11, Vol.120 (21), p.4887-4887

2012

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory Therapy with Combination of Low Dose Thalidomide, Alpha Interferon (IFN-a) and Prednisone Produces Durable Response In Myelofibrosis

Blood, 2010-11, Vol.116 (21), p.4123-4123

2010

Link zum Volltext

Verfügbarkeit prüfen

Additon of Low-Dose Interferon-alpha (LD-IFN-a) and Lenalidomide after Failure to a Combination of Thalidomide and Prednisone in Myelofibrosis with Myeloid Metaplasia (MMM)

Blood, 2007-11, Vol.110 (11), p.4645-4645

2007

Link zum Volltext

Verfügbarkeit prüfen

A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients

Blood, 2012-11, Vol.120 (21), p.4942-4942

2012

Link zum Volltext

Verfügbarkeit prüfen

Granulocyte Colony-Stimulating Factor Induced Differentiation Syndrome Mimicking Acute Myeloid Leukemia and the Unmasking of Chronic Myelomonocytic Leukemia

Blood, 2005-11, Vol.106 (11), p.4428-4428

2005

Link zum Volltext

Verfügbarkeit prüfen

HHV‐8–Associated Multicentric Castleman's Disease in HIV‐Negative Patient: A Novel Therapy for an Orphan Disease

The oncologist (Dayton, Ohio), 2012-01, Vol.17 (1), p.145-146

2012

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Blood, 2013-11, Vol.122 (21), p.1550-1550

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7116-7116

2013

Link zum Volltext

Verfügbarkeit prüfen

Nonanthracycline Induction Chemotherapy (T-FLAG) for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood, 2010-11, Vol.116 (21), p.4356-4356

2010

Link zum Volltext

Verfügbarkeit prüfen

HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease

Blood, 2010-11, Vol.116 (21), p.4897-4897

2010

Link zum Volltext

Verfügbarkeit prüfen

Exploring the lived experiences of Complex Regional Pain Syndrome (CRPS) patients

Besa, Emmanuel Huen

2015

Link zum Volltext
ProQuest

A pilot trial of 13- cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias

Leukemia research, 1998-08, Vol.22 (8), p.741-749

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/ Refractory Acute Leukemias

Blood, 2010-11, Vol.116 (21), p.2192-2192

2010

Link zum Volltext

Verfügbarkeit prüfen

Haploidentical Transplantation In Adults ≥ 66 Years of Age

Blood, 2010-11, Vol.116 (21), p.3529-3529

2010

Link zum Volltext

Verfügbarkeit prüfen

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study

Blood, 2009-11, Vol.114 (22), p.3829-3829

2009

Link zum Volltext

Verfügbarkeit prüfen

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Blood, 2007-11, Vol.110 (11), p.1447-1447

2007

Link zum Volltext

Verfügbarkeit prüfen

Survey of exposure to genotoxic agents in primary myelodysplastic syndrome : correlation with chromosome patterns and data on patients without hematological disease

Cancer research (Chicago, Ill.), 1990-11, Vol.50 (21), p.6876-6881

1990

Link zum Volltext

Verfügbarkeit prüfen

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Blood, 2008-11, Vol.112 (11), p.634-634

2008

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Use in Four Patients with Acquired vonWillebrand's Syndrome

Blood, 2006-11, Vol.108 (11), p.4045-4045

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(77)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(38)
Male
(22)
Female
(21)
Biological And Medical Sciences
(19)
Medical Sciences
(18)
Adult
(16)
Aged
(16)
Middle Aged
(15)
Oncology
(15)
Hematology
(14)
Hematologic And Hematopoietic Diseases
(12)
General & Internal Medicine
(9)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(9)
Medicine, General & Internal
(9)
Time Factors
(7)
Aged, 80 And Over
(6)
Karyotyping
(6)
Animals
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

Macrocytosis Case (Out of Print)

Maintenance Low Dose 13 Cis-Retinoic Acid and Alpha Tocopherol Improves Survival Compared to High Dose Therapy for 6 Months In LOW and INT-1/2 Stage MDS: Role for Prevention Trial

The Use of Infliximab to Control Recurrent Cytokine Storms in EBV-Associated Angioimmunoblastic Lymphoma and Hemophagocytic Syndrome

Immunomodulatory Therapy with Combination of Low Dose Thalidomide, Alpha Interferon (IFN-a) and Prednisone Produces Durable Response In Myelofibrosis

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Additon of Low-Dose Interferon-alpha (LD-IFN-a) and Lenalidomide after Failure to a Combination of Thalidomide and Prednisone in Myelofibrosis with Myeloid Metaplasia (MMM)

A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients

Granulocyte Colony-Stimulating Factor Induced Differentiation Syndrome Mimicking Acute Myeloid Leukemia and the Unmasking of Chronic Myelomonocytic Leukemia

HHV‐8–Associated Multicentric Castleman's Disease in HIV‐Negative Patient: A Novel Therapy for an Orphan Disease

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)

Nonanthracycline Induction Chemotherapy (T-FLAG) for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease

Exploring the lived experiences of Complex Regional Pain Syndrome (CRPS) patients

A pilot trial of 13- cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias

Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/ Refractory Acute Leukemias

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Haploidentical Transplantation In Adults ≥ 66 Years of Age

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Survey of exposure to genotoxic agents in primary myelodysplastic syndrome : correlation with chromosome patterns and data on patients without hematological disease

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Rituximab Use in Four Patients with Acquired vonWillebrand's Syndrome

Suchergebnisse filtern